The Effect of Infections on the Mortality of Cirrhotic Patients with Hepatic Encephalopathy by HUNG, T.H.
The effect of infections on the mortality of cirrhotic patients
with hepatic encephalopathy
T. H. HUNG1,2, C. J. LAY2,3, C. M. CHANG2,4, J .J. TSAI5, C. C. TSAI6
AND C. C. TSAI2,3*
1Division of Gastroenterology, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital,
Chiayi, Taiwan
2School of Medicine, Tzu Chi University, Hualien, Taiwan
3Division of Infectious Diseases, Department of Medicine, Buddhist Dalin Tzu Chi General Hospital,
Chiayi, Taiwan
4Division of General Surgery, Department of Surgery, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
5Division of Gastroenterology, Department of Medicine, National Yang-Ming University Hospital, I-Lan,
Taiwan
6Department of Mathematics, Tamkang University, Tamsui, Taiwan
Received 1 August 2012; Final revision 16 December 2012; Accepted 11 January 2013
SUMMARY
Cirrhotic patients are prone to having infections, which may aggravate hepatic encephalopathy
(HE). However, the effect of infections on mortality in HE cirrhotic patients is not well
described. The National Health Insurance Database, derived from the Taiwan National Health
Insurance Programme, was used to identify 4150 adult HE cirrhotic patients hospitalized between
1 January 2004 and 31 December 2004. Nine hundred and eighty-ﬁve patients (23·7%) had one
or more co-existing infections during their hospitalization. After Cox proportional hazard
regression modelling adjusted by the patients’ gender, age, and medical comorbidity disorders,
the hazard ratios (HRs) in HE patients with infections for 30-day, 30- to 90-day, and 90-day to
1-year mortalities were 1·66 [95% conﬁdence interval (CI) 1·42–1·94], 1·51 (95% CI 1·23–1·85)
and 1·34 (95% CI 1·13–1·58), respectively. Compared to the non-infection group, the HRs of
pneumonia, spontaneous bacterial peritonitis, urinary tract infection, sepsis without speciﬁc focus
(SWSF), cellulitis, and biliary tract infection were 2·11, 1·48, 1·06, 2·21, 1·06, and 0·78, respect-
ively, for 30-day mortality; 1·82, 1·22, 0·93, 2·24, 0·31, and 2·82, respectively, for 30- to 90-day
mortality; and 2·03, 0·82, 1·24, 1·64, 1·14, and 0·60, respectively, for 90-day to 1-year mortality
for HE cirrhotic patients. We conclude that infections increase the mortality of HE cirrhotic
patients, especially pneumonia and SWSF.
Key words: Cirrhosis, hepatic encephalopathy, pneumonia, urinary tract infection, spontaneous
bacterial peritonitis.
INTRODUCTION
Hepatic encephalopathy (HE) develops as cirrhosis
progresses or as a result of portosystemic shunting,
so that the liver cannot detoxify portal venous
blood. Increased byproducts of gut ﬂora such as
ammonia and endotoxin in systemic circulation
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cause cognitive impairment and contribute to poor
survival [1–5]. The incidence of HE ranges from 2%
to 20% per year in decompensated cirrhotic patients,
and the incidence of subclinical HE was reported
to be about 40% in a cross-sectional study of
Child–Pugh grade A cirrhosis [6–8].
Due to widespread derangements of immunity
caused by cirrhosis, cirrhotic patients are prone to
have bacterial infections [9]. In a previous report,
infection episodes were reported in 40% of hospital-
ized cirrhotic patients [10]. Infections in cirrhotic
patients are associated with decrease in hepatic func-
tions and about a fourfold increase in mortality
[11–13]. In addition, severe dehydration and increased
nitrogenous substances caused by infectious diseases
can aggravate the severity of HE [14].
However, the effect of infectious diseases on the
mortality of HE cirrhotic patients is controversial.
In a retrospective study including 333 HE cirrhotic
patients, the patients with co-existing infections had
higher mortality (46·5% vs. 22·7%, P=0·001) [15].
In a prospective study including 100 patients with
cirrhosis and grade 3/4 HE, admitted to a liver
intensive-care unit, cultures were positive in 22/52
(42%) survivors and 19/48 (40%) non-survivors [2].
The former used spontaneous bacterial peritonitis,
urinary tract infection, septicaemia, respiratory tract
infection, and dermatological infection as infectious
diseases, and the latter only used bacteraemia as
infectious diseases. Both studies included a small
population and did not adjust for possible con-
founding factors on the effect of infections on
mortality. In this study, we used a nationwide
population-based database to enrol a large population
of hospitalized patients with chronic liver disease
complicated by cirrhosis and HE, The aims of this
study were (1) to investigate the effect of co-
existing bacterial infections on mortality in hospital-
ized HE cirrhotic patients, and (2) to identify the
effect of different infections on mortality in this
population.
METHODS
Database
In 1995, Taiwan started the National Health Insurance
(NHI) programme. Currently, the National Health
Insurance Bureau (BNHI) covers more than 99% of
the Taiwanese population. All medical records from
all contracted medical institutions must be provided
to the BNHI for medical payment. In accordance
with the regulations governing the review of medical
services, the BNHI reviews reimbursement claims
ﬁled by contracted medical institutions and screens
the type, volume, quality and appropriateness of medi-
cal services provided under the NHI programme.
These medical records are established as a database
(the National Health Insurance Research Database;
NHIRD), which is maintained by BNHI and NHRI.
The dataset in this study is from this database, which
includes all International Classiﬁcation of Diseases,
9th Revision, Clinical Modiﬁcation (ICD-9-CM)
codes of the hospitalized patients in Taiwan. The
NHIRD research committee approved the use of this
database to perform this study (agreement number
100101). The ﬁles from NHIRD did not include the
patients’ and their healthcare providers’ private in-
formation.
Study population
In this retrospective study, we enrolled patients dis-
charged between 1 January 2004 and 31 December
2004 with both diagnostic codes for cirrhosis (ICD-
9-CM code 571·5 or 571·2) and HE (ICD-9-CM
code 572·2). Because the aetiologies of cirrhosis were
very different in young and adult cirrhotic patients,
patients aged <30 years were excluded. Patients with
biliary cirrhosis (ICD-9-CM code 571·6) also were
excluded. Because patients receiving portosystemic
shunts or transjugular intrahepatic portosystemic
shunts were prone to have HE and had higher
HE-associated mortality, they were excluded from
this study. The patients with incomplete or missing
basic data in the database were also excluded.
All enrolled HE cirrhotic patients were divided
into two groups according to whether they had one
or more co-existing infections reported during hospi-
talization. Because we could not identify microbio-
logical information from this database, the patients
receiving antibiotics (but not including antiviral
agents) and having a diagnostic code for an infection
during their hospitalization were considered as having
a co-existing infection. The major infections included
pneumonia (ICD-9-CM code 481–487) [16], sepsis
(ICD-9-CM code 038, 020·0, 790·7 or 112·81) [17],
urinary tract infection (UTI) (ICD-9-CM code
590·1, 595·0, 595·9 or 599·0) [18], biliary tract infec-
tion (BTI) (ICD-9-CM code 576·1, 575·0, 574·00,
574·01, 574·30, 574·31, 574·60, 574·61, 574·80,
574·81), empyema (ICD-9-CM code 510), cellulitis
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(ICD-9-CM code 681 or 682), necrotizing fasciitis
(ICD-9-CM code 728·86), central nervous system
infection (including bacterial meningitis or brain
abscess: ICD-9-CM code 324 or 320), septic arthritis
(ICD-9-CM code 711), infective endocarditis
(ICD-9-CM code 421), perianal abscess (ICD-9-CM
code 566), liver abscess (ICD-9-CM code 572·0)
and spontaneous bacterial peritonitis (SBP) (ICD-
9-CM codes 567·2, 567·8 or 567·9) [19]. Patients
with other diagnostic codes for secondary peritonitis,
such as appendicitis, hollow organ or biliary tract per-
foration, ischaemic bowel disease, peritoneal dialysis
catheter-related peritonitis, as well as those having
an additional procedure code for abdominal surgery,
were not included as having SBP. Patients with diag-
nostic codes for sepsis (ICD-9-CM code 038, 020·0,
790·7 or 112·81) without other diagnostic codes for
an infectious focus were considered to have sepsis
without speciﬁc focus (SWSF).
Because many factors affected the mortality of HE
cirrhotic patients, the following medical disorders
were investigated as possible confounding factors: al-
coholism (ICD-9-CM codes 291, 303, 305·00–305·03,
571·0–571·3), hepatocellular carcinoma (HCC)
(ICD-9-CM code 155·0), acute renal failure (ARF)
(ICD-9-CM code 584, or 572·4), oesophageal variceal
bleeding (OVB) (ICD-9-CM code 456·0, or 456·20),
chronic renal failure (CRF) (ICD-9-CM code 585),
peptic ulcer bleeding (PUB) (ICD-9-CM code
531–533), and ascites (ICD-9-CM code 789·5 or
procedure code 54·91).
Statistical analysis
The SPSS statistical package (SPSS System for
Windows, version 13.0, SPSS Inc., USA) was used
to perform the analyses in this study. The χ2 test or
Fisher’s exact test was used to compare categorical
variables. One-way ANOVA was used to compare
continuous variables. In order to identify risk factors
for mortality, a proportional hazards Cox regression
model was used to control for possible confounding
factors. We present hazard ratios (HRs) with the
95% conﬁdence intervals (CIs) using a signiﬁcance
level of P<0·05. The starting point to evaluate the
30-day, 90-day, and 1-year mortalities in HE cirrhotic
patients was the date of admission for enrolled hospi-
talizations. HRs for mortality were calculated for
comparison between the groups with and without
co-existing infection.
RESULTS
Patients’ characteristics
A total of 4150 HE cirrhotic patients were enrolled in
this study. Their mean age was 57·6±13·8 years and
2976 (71·7%) patients were male. There were 985
(23·7%) patients with co-existing infections during
their hospitalization. The demographic characteristics
and comorbidities of the HE cirrhotic patients with
and without infectious diseases are shown in
Table 1. The infection group had signiﬁcantly more
patients of female gender and ascites. The non-
infection group had signiﬁcantly more patients of
male gender, HCC, and OVB. Other factors, includ-
ing PUB, alcoholism, ARF, CRF, and age were not
signiﬁcantly different between groups. The 30-day,
90-day and 1-year mortalities were 18·0%, 28·9%,
and 46·5%, respectively, in the non-infection group,
and 24·6%, 38·0%, and 57·6%, respectively, in the
infection group.
Prognostic factors of 30-day, 30- to 90-day, and 90-day
to 1-year mortalities
In a Cox proportional regression model, adjusted by
age, gender and other confounding factors, including
HCC, OVB, ascites, alcoholism, ARF, CRF and
PUB, the HR of a co-existing infection on 30-day
mortality was 1·66 (95% CI 1·32–1·94, P<0·001).
In order to evaluate the late effect of infection on
Table 1. Demographic characteristics for hospitalized
cirrhotic patients with hepatic encephalopathy and with
or without co-existing infections (n=4150)
Co-existing
infection
(n=985)
No
infection
(n=3165)
P
value
Male, n (%) 653 (66·3) 2323 (73·4) <0·001
Age, yr 58·4±14·0 57·4±13·7 0·052
HCC, n (%) 132 (13·4) 730 (23·1) <0·001
OVB, n (%) 123 (12·5) 503 (15·9) 0·009
Ascites, n (%) 324 (32·9) 755 (23·9) <0·001
CRF, n (%) 36 (3·7) 121 (3·8) 0·809
ARF, n (%) 34 (3·5) 132 (4·2) 0·315
Alcoholism,
n (%)
253 (25·7) 883 (27·9) 0·174
PUB, n (%) 49 (5·0) 183 (5·8) 0·335
HCC, Hepatocellular carcinoma; OVB, oesophageal vari-
ceal bleeding; CRF, chronic renal failure; ARF, acute
renal failure; PUB, peptic ulcer bleeding.
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mortality, we calculated the 90-day mortality of
patients surviving >30 days and the 1-year mortality
of patients surviving >90 days. The HRs of infection
for 30- to 90-day and 90-day to 1-year mortalities
were 1·51 (95% CI 1·23–1·85, P<0·001), and 1·34
(95% CI 1·13–1·58, P<0·001), respectively (Table 2).
We found that the effect of infection on the mortality
of HE cirrhotic patients was persistent but decreased
over time. Figure 1 shows the cumulative survival
plot for HE cirrhotic patients with and without
co-existing infections.
The other signiﬁcant risk factors for 30-day, 30- to
90-day, and 90-day to 1-year mortalities of HE cir-
rhotic patients are listed in Table 2. Age and HCC
were consistent risk factors for mortality in HE cir-
rhotic patients. Male gender and OVB were risk
factors for the 30-day mortality but not for 30- to
90-day and 90-day to 1-year mortalities. ARF was a
risk factor for 30-day and 30- to 90-day mortalities,
but not for 90-day to 1-year mortality. Alcoholism
was negatively associated with mortality of HE
cirrhotic patients.
Table 2. Prognostic factors of 30-day, 30- to 90-day, and 90-day to 1-year mortalities in hospitalized cirrhotic
patients with hepatic encephalopathy
30-day mortality 30- to 90-day mortality 90-day to 1-year mortality
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Infection 1·66 (1·42–1·94) <0·001* 1·51 (1·23–1·85) <0·001* 1·34 (1·13–1·58) 0·001*
Age 1·01 (1·00–1·01) 0·028* 1·02 (1·01–1·03) <0·001* 1·02 (1·01–1·02) <0·001*
Male gender 1·37 (1·16–1·62) <0·001* 1·21 (0·99–1·49) 0·070 1·06 (0·90–1·26) 0·478
HCC 2·24 (1·93–2·61) <0·001* 3·21 (2·64–3·90) <0·001* 1·69 (1·40–2·03) <0·001*
OVB 1·59 (1·33–1·89) <0·001* 1·28 (0·98–1·66) 0·067 0·98 (0·79–1·22) 0·855
Ascites 0·98 (0·84–1·14) 0·760 1·65 (1·37–2·00) <0·001* 1·40 (1·19–1·64) <0·001*
Alcoholism 0·66 (0·55–0·81) <0·001* 0·70 (0·53–0·91) 0·009 0·86 (0·71–1·03) 0·105
ARF 3·61 (2·90–4·47) <0·001* 2·92 (1·98–4·32) <0·001* 1·49 (0·90–2·44) 0·118
CRF 0·77 (0·51–1·15) 0·196 2·09 (1·23–1·85) <0·001* 1·94 (1·43–2·64) <0·001*
PUB 0·94 (0·68–1·30) 0·715 1·33 (0·91–1·94) 0·142 0·953 (0·69–1·32) 0·769
HR, Hazard ratio; CI, conﬁdence interval; HCC, hepatocellular carcinoma; OVB, oesophageal variceal bleeding; CRF,
chronic renal failure; ARF, acute renal failure; PUB, peptic ulcer bleeding.
*P<0·05.
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Fig. 1. Cumulative survival plot for hepatic encephalopathy cirrhotic patients with and without co-existing infections.
After Cox regression modelling, adjusted by age, gender, and other confounding factors, the hazard ratios of infectious
diseases for 30-day, 30- to 90-day, and 90-day to 1-year mortalities were 1·66 (95% CI 1·32–1·94, P<0·001), 1·51 (95% CI
1·23–1·85, P<0·001), and 1·34 (95% CI 1·13–1·58, P<0·001), respectively.
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The demographic characteristics of cirrhotic patients
with variable infections
In a total of 985 HE cirrhotic patients with infectious
diseases, there were 146 (14·8%) patients with pneu-
monia, 239 (24·3%) patients with UTI, 167 (17·0%)
patients with SBP, 317 (32·2%) patients with SWSF,
39 (4·0%) patients with cellulitis, 23 (2·3%) patients
with BTI, while the remaining patients had other
infectious diseases (1·6%) or dual infections (3·9%).
The 30-day, 90-day, and 1-year mortalities of HE
cirrhotic patients with different infections are given
in Table 3.
The effects of different infections on mortality
After Cox proportional regression modelling adjusted
for age, gender and other confounding factors, includ-
ing HCC, OVB, ascites, alcoholism, ARF, CRF and
PUB, the results of HRs of different infections on
the mortality of HE cirrhotic patients are shown in
Table 4. The HR of SWSF for 30-day mortality of
HE cirrhotic patients was highest, followed by pneu-
monia and SBP. However, the HR of BTI for 30- to
90-day mortality was highest, followed by SWSF,
and pneumonia. The HR of pneumonia for 90-day
to 1-year mortality was highest, followed by SWSF.
Figure 2 shows the cumulative survival plot for HE
cirrhotic patients with different infections. We found
that the effects of pneumonia and SWSF on the mor-
tality of HE cirrhotic patients persisted over time.
DISCUSSION
In-patient mortality was about 15% in infected
cirrhotic patients in a previous study [10]. When HE
cirrhotic patients had co-existing infections, our
Table 3. The 30-day, 90-day and 1-year mortalities of different infections in
hospitalized cirrhotic patients with hepatic encephalopathy
Condition
Number
(%)
30-day
mortality (%)
90-day
mortality (%)
1-year
mortality (%)
Non-infection 3165 (76·3) 18·0 28·9 46·5
Infection 985 (23·7) 24·6 38·0 57·6
Pneumonia 146 (14·8) 33·6 47·3 69·2
UTI 239 (24·3) 15·5 25·1 48·3
SBP 167 (17·0) 23·4 38·3 54·5
SWSF 317 (32·2) 30·6 45·7 64·0
Cellulitis 39 (4·0) 12·8 15·4 38·5
BTI 23 (2·3) 13·0 39·4 47·8
Other 16 (1·6) 18·8 31·3 43·8
Dual infections 38 (3·9) 23·7 42·1 57·9
UTI, Urinary tract infection; SBP, spontaneous bacterial peritonitis; SWSF, sepsis
without speciﬁc focus; BTI, biliary tract infection.
Table 4. Adjusted hazard ratios of different infections on 30-day, 30- to 90-day, and 90-day to 1-year mortalities of
cirrhotic patients with hepatic encephalopathy, compared to those without co-existing infections
30-day mortality
HR (95% CI)
P
value
30- to 90-day mortality
HR (95% CI)
P
value
90-day to 1-year mortality
HR (95% CI)
P
value
SBP 1·48 (1·07–2·05) 0·019* 1·22 (0·79–1·88) 0·375 0·82 (0·55–1·223) 0·339
Pneumonia 2·11 (1·57–2·83) <0·001* 1·82 (1·15–2·87) 0·010* 2·03 (1·42–2·91) <0·001*
UTI 1·06 (0·75–1·49) 0·761 0·93 (0·60–1·43) 0·737 1·24 (0·94–1·65) 0·129
SWSF 2·21 (1·78–2·75) <0·001* 2·24 (1·65–3·05) <0·001* 1·64 (1·25–2·16) <0·001*
Cellulitis 1·06 (0·44–2·56) 0·899 0·31 (0·04–2·21) 0·243 1·14 (0·59–2·19) 0·707
BTI 0·78 (0·25–2·44) 0·673 2·82 (1·25–6·36) 0·012* 0·60 (0·15–2·41) 0·473
HR, Hazard ratio; CI, conﬁdence interval; SBP, spontaneous bacterial peritonitis; SWSF, sepsis without speciﬁc focus; UTI,
urinary tract infection; BTI, biliary tract infection.
*P<0·05.
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study shows that their 30-day mortality was 24·6%,
90-day mortality 38%, and 1-year mortality 57·6%.
After adjusting for other possible confounding factors
for mortality, our study shows that co-existing infec-
tions increase mortality in hospitalized HE cirrhotic
patients. We also found that the effect of different
types of infection on mortality in HE cirrhotic
patients was different.
In accord with previous studies, UTI and cellulitis
had the lowest 30-day mortality in HE cirrhotic
patients, and SWSF and pneumonia carried the high-
est 30-day mortality [15, 20]. The present study also
shows that SWSF and pneumonia had a higher
90-day and 1-year mortality than other infections.
Aspiration of gastric content to induce aspiration
pneumonia is a severe complication in HE patients
[21]. It can induce pulmonary inﬂammation, capillary
leakage, and oxidative damage which cause acute lung
injury [22, 23]. Besides acute effects, aspiration pneu-
monia can also cause permanent lung damage, which
may contribute to the persistent effect of pneumonia
on the mortality of HE cirrhotic patients [24–26].
Interestingly, BTI increased the HR for 30- to
90-day mortality, but not for early or late mortality.
Biliary tract occlusion is the major cause of BTI.
When BTI occurs, patients may require adequate
drainage and antibiotics to prolong their survival.
However, it is difﬁcult for cirrhotic patients with
biliary tract occlusion to have the cause of occlusion
removed due to the high risk of anesthesia and
surgery. When drug-resistant pathogens emerge or a
disease progresses, mortality is increased. That may
be the reason why the 30- to 90-day mortality of HE
cirrhotic patients with BTI was signiﬁcantly increased.
The other predisposing factors for mortality of HE
cirrhotic patients were age, male gender, HCC, OVB,
non-alcoholic-related cirrhosis, and ARF. Of these,
ARF was the most unfavourable prognostic factor
for 30-day mortality. This result was compatible
with a previous study [2]. ARF is an important
marker for severity of disease and is associated with
sepsis-related mortality [27, 28]. In addition, ARF
can impair the renal function to clear ammonia and
increase the susceptibility of aggravating brain
oedema in HE cirrhotic patients [29, 30]. However,
our study shows the effects of ARF are conﬁned to
early mortality, not late mortality. By contrast, CRF
was associated with an increased risk of late but not
early mortality.
Our study provides evidence that co-existing infec-
tions increase the risk of mortality in hospitalized
HE cirrhotic patients; furthermore, the mortality
risk varied by type of infection. Nonetheless, there
are several limitations in our study. First, it was not
possible to identify the Child–Pugh score according
to the diagnostic ICD-9 codes in the database,
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Fig. 2. Cumulative survival plot for hepatic encephalopathy cirrhotic patients with different infections. After Cox
regression modelling, the hazard ratios (HRs) of pneumonia for 30-day, 30- to 90-day, and 90-day to 1-year mortalities
were 2·11, 1·82, and 2·03, respectively; the HRs of urinary tract infections were 1·06, 0·93, and 1·24, respectively; the HRs
of sepsis without speciﬁc focus were 2·21, 2·24, and 1·64, respectively; the HRs of spontaneous bacterial peritonitis were
1·48, 1·22, and 0·82, respectively; the HRs of cellulitis were 1·06, 0·31, and 1·14, respectively; and the HRs of biliary tract
infection were 0·78, 2·82, and 0·60, respectively compared to the non-infection group.
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although the Child–Pugh score in HE cirrhotic
patients was not shown to be associated with outcome
in previous studies [2, 31]. Second, the aetiology for
cirrhosis in Taiwan is known mostly to be related to
chronic vial hepatitis, e.g. hepatitis B virus and hepa-
titis C virus [32]. However, the exact aetiology of liver
cirrhosis could not be identiﬁed in this population-
based study, even though there were 27% cirrhotic
patients with a diagnostic code for alcoholism.
Third, it was impossible to evaluate the grade of HE
in this database. Finally, the database used in the pre-
sent study could not provide microbiological data.
Therefore, we were unable to discover the pathogens
causing infection in HE cirrhotic patients. Despite
these limitations, this study is the ﬁrst complete
nationwide population-based study to identify the
relationship of infections and mortality in hospitalized
HE cirrhotic patients. In conclusion, co-existing infec-
tions, particularly pneumonia and SWSF, increase the
30-day, 30- to 90-day, and 90-day to 1-year mortality
risk of hospitalized HE cirrhotic patients.
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